You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Glutaminase Inhibitor

Showing 1 - 25 of 7,367
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of

Active, not recruiting
  • Acute Myeloid Leukemia With Multilineage Dysplasia
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 25, 2022

Ovarian Cancer, Resistant BRCA Wild-Type Ovarian Cancer Trial in Birmingham (Cohort 1: Dose Escalation, Cohort 2: Dose

Terminated
  • Ovarian Cancer
  • Resistant BRCA Wild-Type Ovarian Cancer
  • Cohort 1: Dose Escalation
  • Cohort 2: Dose Escalation
  • Birmingham, Alabama
    University of Alabama at Birmingham
Apr 29, 2022

Solid Tumors, NSCLC, CRC Trial in United States (Telaglenestat (CB-839), Palbociclib Oral Capsule or Tablet [Ibrance])

Completed
  • Solid Tumors
  • +3 more
  • Telaglenestat (CB-839)
  • Palbociclib Oral Capsule or Tablet [Ibrance]
  • Santa Monica, California
  • +9 more
Sep 14, 2022

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Pharmacodynamic Study
  • Telaglenastat Hydrochloride
  • Birmingham, Alabama
  • +30 more
Sep 1, 2022

Colorectal Cancer, Metastatic Colorectal Cancer, RAS Wild Type Colorectal Cancer Trial in Nashville (drug, biological, other,

Recruiting
  • Colorectal Cancer
  • +3 more
  • Glutaminase Inhibitor CB-839
  • +5 more
  • Nashville, Tennessee
    Vanderbilt-Ingram Cancer Center
Mar 29, 2022

Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer Trial in United States (CB-839, Talazoparib)

Terminated
Has Results
  • Solid Tumor
  • +6 more
  • Birmingham, Alabama
  • +8 more
Feb 16, 2022

Leptomeningeal Tumor, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain Trial in United States

Recruiting
  • Leptomeningeal Neoplasm
  • +6 more
  • Duarte, California
  • +6 more
Dec 29, 2022

Prostate Cancer Metastatic Trial in Boston (Telaglenastat, Talazoparib)

Not yet recruiting
  • Prostate Cancer Metastatic
  • Boston, Massachusetts
    Massachusetts General Hospital
Mar 27, 2021

Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in United

Recruiting
  • Advanced Lung Non-Small Cell Carcinoma
  • +2 more
  • Birmingham, Alabama
  • +10 more
Jan 25, 2023

Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer Trial in United States (Paclitaxel, CB-839)

Completed
Has Results
  • Triple Negative Breast Cancer
  • TNBC - Triple-Negative Breast Cancer
  • Birmingham, Alabama
  • +24 more
Sep 19, 2022

Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3 Trial in United States (other, radiation, drug)

Active, not recruiting
  • Astrocytoma, IDH-Mutant, Grade 2
  • Astrocytoma, IDH-Mutant, Grade 3
  • Questionnaire Administration
  • +3 more
  • Phoenix, Arizona
  • +24 more
Dec 7, 2022

Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, NSCLC (NSCLC) Trial in United States (CB-839, Nivolumab)

Completed
  • Clear Cell Renal Cell Carcinoma (ccRCC)
  • +2 more
  • Scottsdale, Arizona
  • +16 more
Aug 16, 2021

Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Tumor Trial in Houston

Recruiting
  • Advanced Endometrial Carcinoma
  • +36 more
  • Glutaminase Inhibitor IPN60090
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Sep 9, 2021

NSCLC, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Tumor of Lung Trial in United States (drug,

Terminated
  • Non-Small Cell Lung Cancer
  • +5 more
  • Birmingham, Alabama
  • +101 more
Mar 8, 2022

Clear Cell Renal Cell Carcinoma Trial in United States (Placebo, CB-839, everolimus)

Completed
  • Clear Cell Renal Cell Carcinoma
  • Placebo
  • +2 more
  • Tucson, Arizona
  • +37 more
Aug 16, 2021

Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma Trial in Worldwide (CB-839, Cabozantinib, Placebo)

Completed
  • Advanced Renal Cell Carcinoma
  • Metastatic Renal Cell Carcinoma
  • Birmingham, Alabama
  • +132 more
Aug 18, 2021

Cardiac Safety Trial in Belfast (telaglenastat, telaglenastat , moxifloxicin)

Completed
  • Cardiac Safety
  • Belfast, Ireland, United Kingdom
    Celerion
Mar 8, 2021

Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM) Trial in United States (CB-839, CB-839 and

Completed
  • Non-Hodgkin's Lymphoma (NHL)
  • +4 more
  • Scottsdale, Arizona
  • +6 more
Jul 16, 2018

Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Peripheral T Cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing/China, China
  • +1 more
Oct 9, 2023

Cutaneous T-cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Cutaneous T-cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 8, 2023

Drug Interaction Trial in Brisbane (Telaglenastat, Famotidine, Placebo for famotidine)

Completed
  • Drug Interaction
  • Brisbane, Queensland, Australia
    Nucleus Network Brisbane Clinic (formerly Q-Pharm)
Mar 8, 2021

Cervical Cancer Trial in Amsterdam (Anti-PD-1 antibody balstilimab)

Not yet recruiting
  • Cervical Cancer
  • Anti-PD-1 antibody balstilimab
  • Amsterdam, Netherlands
    Amsterdam UMC
Oct 17, 2023

Hepatocellular Carcinoma (HCC) Trial in Taiwan (Chidamide, Regorafenib)

Recruiting
  • Hepatocellular Carcinoma (HCC)
  • Kaohsiung, Taiwan
  • +4 more
Mar 14, 2023

HIV Trial in Las Vegas, Austin (VH4004280, Placebo)

Not yet recruiting
  • HIV Infections
  • Las Vegas, Nevada
  • +1 more
Aug 21, 2023

Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer Trial (OP-1250, Fulvestrant, Anastrozole)

Not yet recruiting
  • Breast Cancer
  • +4 more
  • (no location specified)
Aug 31, 2023